Understanding this basic pharmacology helps you choose a dosing routine that fits your real life
In a rodent model, a novel GLP-1R/GIPR/GCGR triple agonist, SAR441255, has been shown to promote weight loss and the maintenance of healthy blood glucose levels and is superior to the GLP-1R/GCGR dual agonist (Bossart et al., 2022)
This is risky and not recommended, as compounded GLP-1 medications are linked to cases of hospitalizations , the FDA warns
This creates a unique window of opportunity
Sloop KW, Briere DA, Emmerson PJ, Willard FS
Patients who jump from lower to higher tirzepatide doses within weeks experience sharper neurochemical shifts than those on gradual escalation schedules